---
title: "Carisma Therapeutics 于 6 月 26 日通知诺华制药终止公司与诺华制药之间的制造和供应协议"
description: "Carisma Therapeutics 已于 2024 年 7 月 31 日终止了与诺华制药的制造和供应协议。该公司现在将专注于其后续产品候选药物 CT-0525，用于体外肿瘤临床开发。其针对 CT-0508 的一期临床试验的新患者招募已暂停"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/207818143.md"
published_at: "2024-07-02T21:01:51.000Z"
---

# Carisma Therapeutics 于 6 月 26 日通知诺华制药终止公司与诺华制药之间的制造和供应协议

> Carisma Therapeutics 已于 2024 年 7 月 31 日终止了与诺华制药的制造和供应协议。该公司现在将专注于其后续产品候选药物 CT-0525，用于体外肿瘤临床开发。其针对 CT-0508 的一期临床试验的新患者招募已暂停

7 月 2 日 (路透社) - Carisma Therapeutics Inc (CARM.O) :

## CARISMA THERAPEUTICS：于 6 月 26 日通知诺华制药终止公司与诺华制药之间的制造和供应协议

## CARISMA THERAPEUTICS INC - 公司与诺华制药之间的制造和供应协议终止，自 2024 年 7 月 31 日起生效

## CARISMA THERAPEUTICS - 公司决定将外体肿瘤临床开发工作集中在其后续产品候选 CT-0525 上

CARISMA THERAPEUTICS INC - 已暂停其 CT-0508 一期临床试验的新患者招募

### Related Stocks

- [CARM.US - Carisma Therapeutics](https://longbridge.com/zh-CN/quote/CARM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down | Carisma Therapeutics Inc. has announced separation agreements for its CEO Steven Kelly and CSO Michael Klichinsky as the | [Link](https://longbridge.com/zh-CN/news/261316519.md) |
| Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview | Carisma Therapeutics Inc is anticipated to report a loss of 12 cents per share for the quarter ending September 30, 2025 | [Link](https://longbridge.com/zh-CN/news/264052760.md) |
| Carisma Therapeutics Amends Agreement with Moderna, Receives $4 Million Payment | Carisma Therapeutics Inc. has amended its Collaboration and License Agreement with ModernaTX, Inc., effective September  | [Link](https://longbridge.com/zh-CN/news/257933444.md) |
| Carisma Therapeutics Delists Common Stock | Carisma Therapeutics Inc. has filed to deregister its common stock, terminating its reporting obligations as a public co | [Link](https://longbridge.com/zh-CN/news/270996498.md) |
| Ocugen Inc. Announces Termination of Merger Agreement with Carisma Therapeutics Due to Funding Shortfall | Ocugen Inc. has terminated its merger agreement with Carisma Therapeutics due to a funding shortfall. The merger, initia | [Link](https://longbridge.com/zh-CN/news/257950392.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
